Podcasts about wegovy

Over the past several years, the rise of GLP-1 drugs such as Ozempic and Wegovy has changed the conversation around weight and obesity in the U.S. Rachel Goldman, PhD, talks about how GLP-1s work; the effects they can have on mental health; what questions to ask if you're considering trying these medications; how weight loss can shift people's relationships with their family, friends and partners; and why there's still stigma around the use of GLP-1s and how patients can navigate that. Find Dr. Rachel's new book at When Life Happens: The Mindset Shift You Need to Manage Stress, Build Confidence, and Break Free. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a text When doctors recommend weight loss, they describe the supposed benefits but remain silent about the harms—reduced metabolism, increased appetite, hormonal disruption, eating disorders, and profound mental health impacts. This ethical failure extends beyond outdated diet advice to newer interventions like GLP-1 medications, where we celebrate short-term metabolic improvements while ignoring gastrointestinal distress, financial burden, social isolation, and unknown long-term consequences. In this episode, Asher challenges the dangerous assumption that fat people should suffer to become thinner, exposing how this narrative serves the weight loss industry's profits while treating fat bodies as unworthy of basic ethical consideration in healthcare. Got a question for the next podcast? Let me know! Connect With Me WEEKLY NEWSLETTER: Get a free script when you sign up THE WEIGHTING ROOM: A community where authenticity thrives and every voice matters The CONSULTING ROOM: Get answers to all your medical questions via DM or Voice Note PLUS access to my entire library of paid resources CONSULTATION: For the ultimate transformation in your healthcare journe THE WEIGH FORWARD: For people who are being denied surgery because of their weight FREE GUIDES:Evidence-based, not diet nonsense Find me on Instagram, YouTube, and LinkedIn.

Welcome back to The Weight Loss Collab! In today's episode, bariatric surgeon and obesity medicine expert Dr. Dovec is diving deep into the world of GLP-1 medications—those popular injectables like Ozempic, Wegovy, Zepbound, and Mounjaro that everyone's been talking about. Whether you're fresh out of bariatric surgery, struggling with weight plateaus, have a lower or higher BMI, or you're just curious if these meds might be right for you, Dr. Dovec breaks down exactly how GLP-1s work, who benefits most, potential side effects, and how to personalize your treatment for the best results. Plus, she compared options like phentermine and Contrave, and gives real talk about surgery versus medication. If you're looking for up-to-date, honest guidance on weight loss medications and a supportive community cheering you on, this episode is packed with insights and actionable advice!

In this powerful episode, I will break down one of the biggest developments in obesity and diabetes treatment in U.S. history. Two major pharmaceutical companies - Eli Lilly and Novo Nordisk - have reached a groundbreaking agreement with the administration that will drastically reduce the prices of popular medications like Wegovy, Ozempic, and Zepbound. This pricing model could transform how obesity medications are covered, distributed, and accessed across Medicare, Medicaid, and direct-to-consumer platforms. Tune in to learn what this new deal means for patients, healthcare providers, and public health overall—and why it's being called a game changer for people struggling with obesity and related health conditions. Episode Highlights: Major price cuts announced for Wegovy, Ozempic, and Zepbound under a new federal deal   Medicare to cover obesity drugs for the first time through a five-year pilot program   Medicaid given the option to join discounted pricing starting 2026   Team Rx launches a direct-to-consumer model cutting out costly middlemen   Lower cash prices for GLP-1 medications and upcoming oral versions   Eli Lilly and Novo Nordisk to invest billions in U.S. manufacturing   Program expected to improve access, affordability, and supply of obesity and diabetes meds   Ongoing push for the Treat and Reduce Obesity Act to expand national coverage   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In Part 1 we looked at an early study of GLP1 drugs and muscle loss. Today we'll look at two more recent studies, one for Eli Lilly's drug tirzepatide and one for Novo Nordisk's drug semaglutide. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

In this episode, Michael Smerconish discusses the political and social landscape in America, focusing on the varying definitions and acceptability of socialism. He explores the recent Democratic victories in major states and the differing approaches within the party, emphasizing the need for policies that appeal beyond urban areas. Smerconish interviews political consultant Frank Luntz on framing socialism to Middle America and delves into changing perceptions between capitalism and socialism. Additionally, he examines economic pressures and the impact of AI on the workforce, highlighting rising pessimism and comparisons with Nordic social democracies. The episode also addresses issues faced by young men today, featuring a conversation with Scott Galloway on their struggles and a call for male role models. Finally, it touches on the costs and benefits of weight loss drugs like Ozempic and Wegovy, suggesting broader access could save money and lives. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Welcome to Ozempic Weightloss Unlocked, the podcast where we break down the latest developments in semaglutide medications and what they mean for your health. I'm your host, and today we're diving into the most important updates from 2025.Let's start with what's working. Ozempic continues to demonstrate significant effectiveness for weight loss, producing mean weight reduction of fourteen point nine to seventeen point four percent over sixty eight weeks in people without diabetes. The higher dose formulation, known as Wegovy, shows even more impressive results, with studies consistently showing greater average weight loss compared to the lower doses found in Ozempic. For millions managing type two diabetes or seeking weight management solutions, these medications have become game changers.But here's what listeners need to know right now. Recent research is raising important safety concerns that demand our attention. A June 2025 study published in JAMA Ophthalmology found that patients taking semaglutide were twice as likely to develop neovascular age related macular degeneration, a condition that gradually destroys central vision. While the absolute risk remains small, researchers from the University of Toronto identified this link as statistically significant. The mechanism makes sense too. Semaglutide alters vascular and inflammatory pathways directly implicated in macular degeneration.The vision concerns aren't the only ones. A January 2025 study in JAMA Otolaryngology found that patients initiating Glucagon like Peptide One receptor agonist therapy had a significantly increased risk of thyroid cancer diagnosis within the first year of use compared to other diabetes medications. Researchers analyzed data from over three hundred fifty thousand adults with type two diabetes.Then there's gastroparesis, the stomach paralysis condition that's become central to ongoing litigation. Multiple lawsuits allege that Novo Nordisk, the manufacturer, failed to provide adequate warnings about this risk. The lawsuits argue the company knew or should have known about the potential link based on clinical studies and medical literature. Patients reported persistent vomiting, nausea, and extreme stomach discomfort after starting the medication.The legal landscape shifted in December 2024 when the Judicial Panel on Multidistrict Litigation ruled to expand the Glucagon like Peptide One receptor agonist lawsuit to include claims involving Saxenda, though blood clot related injuries were excluded due to complexity concerns.What does this mean for you? If you're considering Ozempic or Wegovy, talk to your doctor about these emerging risks alongside the proven benefits. If you're already taking these medications and experiencing vision changes, thyroid issues, or stomach problems, document everything and consult your healthcare provider.The story of Ozempic isn't finished. As evidence emerges, companies face questions not just about what they disclosed but about what they should have investigated. The scientific community continues watching as more data arrives.Thank you so much for tuning in to Ozempic Weightloss Unlocked. Please subscribe to stay updated on the latest developments in semaglutide research and safety updates. This has been a Quiet Please production. For more, check out Quiet Please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Three more suspects, including two affluent New Jersey teens, are now charged in a foiled ISIS-inspired Halloween terror plot, bringing the total to five. The FAA is cutting up to 10% of flights at 40 major airports as the government shutdown enters week six, triggering nationwide delays. President Trump announces a deal with Eli Lilly and Novo Nordisk to slash the cost of popular GLP-1 weight-loss drugs like Wegovy and Ozempic to about $350 through a new program called TrumpRX. Former House Speaker Nancy Pelosi, 85, announces she will not seek reelection after nearly four decades in Congress and two impeachments of President Trump. Geviti: Go to https://gogeviti.com/megynand get 20% off with code MEGYN. Walmart: Learn how Walmart is fueling the future of U.S. manufacturing at https://Walmart.com/America-at-work Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Andrew Walworth, Tom Bevan and Carl Cannon discuss new polling on candidate preferences for the 2028 presidential nomination for both parties, and this morning's reporting from Politico that Secretary of State Marco Rubio is telling close associates that he believes Vice President JD Vance is the frontrunner for the Republican nomination. Then, they talk about the role of energy prices in last Tuesday's election, and President Donald Trump's new agreement with pharmaceutical manufacturers to sell GLP-1 products like Wegovy and Zepbound at discounted prices to Medicare and Medicaid recipients. Then finally, the guys discuss the jury verdict in Washington, DC of the former Justice Department employee who threw a sandwich at a federal officer in protest last August. Plus, this week's “You Cannot Be Serious” stories. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

A 37 días del cierre del gobierno, la administración Trump confirmó que a partir de mañana se reducirá el tráfico aéreo en un 10% afectando al menos 40 aeropuertos del país. Al menos 500 vuelos serán cancelado en el primer día de la medida. Un juez de Rhode Island le ordenó al gobierno Trump conseguir los fondos necesarios para financiar los beneficios del programa de asistencia nutricional SNAP.El cierre del gobierno también podría impedir que al menos 6 millones de familias de bajos recursos puedan pagar la electricidad y la calefacción en las próximas semanas por la falta de fondos del programa LIHEAP.En otras noticias: La jueza Sarah Ellis confirmó que el comandante de la patrulla fronteriza Gregory Bovino admitió mentir sobre el uso de gas lacrimógeno. La jueza limitó el uso de la fuerza a los agente federales en Chicago.

GET YOUR WAV WATCH HERE: https://buy.wavwatch.com/WAM Use Code WAM to save $100 and purchase amazing healing frequency technology! GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/ USE Code WAM to save 5% plus free shipping! BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ Avoid CBDCs! Get Your SUPER-SUPPLIMENTS HERE: https://vni.life/wam Use Code WAM15 & Save 15%! Life changing formulas you can't find anywhere else! HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-keep-wam-alive/# Josh Sigurdson reports on the new announcement by President Donald Trump regarding steep discounts for Ozempic, the weight loss drug. While people like RFK Jr. had for years called for subsidizing organic food rather than Ozempic, Trump feels differently. The President announced a deal with Ozempic which would involve lower prices making it more affordable and more easy to obtain via insurance policies. The problem? Ozempic is incredibly bad for you. What happened to Trump being against pharma? After giving $7 billion to Pfizer recently, he's now doubling down on his doublethink. Ozempic which comes from REPTILE VENOM (to be specific, Gila Monster venom) helps people lose weight. Though at the same time, it causes Ozempic Face which strangely makes people look like reptiles. Far worse than that, it's been tied to sudden blindness, kidney cancer, digestive issues and organ failure. The drug was meant for diabetes alongside Wegovy until it was noticed that it actually lead to weight loss. The lizard venom peptides can lead to serious side effects. This is not what people voted for when they supported Trump, but of course it's not. Why would anyone be surprised? Meanwhile, as Trump made the announcement, a man collapsed behind him. Dr. Oz ran to the rescue as RFK Jr. left the room. You can't make this stuff up... well actually you can... It's all theater. Stay tuned for more from WAM! Get local, healthy, pasture raised meat delivered to your door here: https://wildpastures.com/promos/save-20-for-life/bonus15?oid=6&affid=321 USE THE LINK & get 20% off for life and $15 off your first box! DITCH YOUR DOCTOR! https://www.livelongerformula.com/wam Get a natural health practitioner and work with Christian Yordanov! Mention WAM and get a FREE masterclass! You will ALSO get a FREE metabolic function assessment! GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Use code JOSH to save money! SIGN UP FOR HOMESTEADING COURSES NOW: https://freedomfarmers.com/link/17150/ Get Prepared & Start The Move Towards Real Independence With Curtis Stone's Courses! GET YOUR FREEDOM KELLY KETTLE KIT HERE: https://patriotprepared.com/shop/freedom-kettle/ Use Code WAM and enjoy many solutions for the outdoors in the face of the impending reset! PayPal: ancientwonderstelevision@gmail.com FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson PURCHASE MERECHANDISE HERE: https://world-alternative-media.creator-spring.com/ JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media For subscriber only content! Pledge here! Just a dollar a month can help us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2025

Today on America in the MorningShutdown Flight Delays On a day when the Senate is hoping to vote later today on ending the government shutdown, today is the day that the FAA has ordered flights to be cut due to staffing shortages.  Yesterday, there were 200 canceled flights across the nation – today that number is expected to be above one thousand, with thousands more delayed.  Correspondent Ed Donahue reports that air traffic controllers and TSA agents received a zero paycheck for the second time since the government shutdown began, and Transportation Secretary Sean Duffy, speaking on Fox News, says the flight cutback is all about air safety.   Pelosi's Retirement After nearly 40 years on Capitol Hill, Nancy Pelosi is retiring from Congress.  Correspondent Clayton Neville reports.   Musk's Big Payday The world may soon have its first “Trillionaire.”  Joan Jones has the story of Elon Musk's payday approval granted by Tesla shareholders.   NFL Player's Suicide There is shock through the sports world after 24-year-old Dallas Cowboys defensive end Marshawn Kneeland took his own life after being involved in a police chase.  The story from correspondent Gethin Coolbaugh.   Senate Blocks Venezuela Measure The Senate has blocked a measure to limit military action by the Trump administration against Venezuela.   Hoagie Hurler Cleared Justice is served for a man who hurled a hoagie at a federal immigration agent in Washington.  The details from correspondent Jennifer King.     Latest On SNAP & Government Shutdown Senators appear closer to ending the government shutdown, now in its 38th day, as a vote is expected later today on a deal that could re-open the government, but it's far from certain enough Democrats are on board.  John Stolnis has more from Washington.   Virginia Teacher's Day In Court A jury awarded $10 million dollars in a civil case to a Virginia teacher who was shot by a first grade student in 2023.  As correspondent Haya Panjwani reports Abagail Zwerner still has a bullet inside her chest from that shooting, and her legal team, speaking outside the courthouse, says her long ordeal is far from over – audio courtesy of Court TV.   Heritage Foundation Fallout The fallout continues surrounding the conservative think tank The Heritage Foundation following an interview by Tucker Carlson with Nick Fuentes.  Correspondent Clayton Neville reports.   SCOTUS On Passports The Supreme Court on Thursday allowed the Trump administration to require the sex designation on US passports to align with a traveler's biological sex, a blow to transgender and non-binary Americans who have argued the policy is unconstitutional.   Trump's Drug Deal At the White House, President Trump unveiled a new deal to expand coverage and lower costs on obesity drugs including Wegovy and Zepbound.  Lisa Dwyer reports.    New Member Of Abraham Accords The White House announced that Kazakhstan will agree to normalizing relations with Israel and join the Abraham Accords, joining the United Arab Emirates, Bahrain, and Morocco who formalized relations with Israel during President Trump's first term in office. Learn more about your ad choices. Visit podcastchoices.com/adchoices

New Zealand has the third highest adult obesity rate in the OECD, and the rates are going up. One in three adult New Zealanders is classified as obese, and one in 10 children. Even if you take into account, yes, yes, yes, a lot of the All Blacks front row are considered obese if you use the BMI. And yes, you might have a slow metabolism or it's your hormones and there's nothing you can do about it, that's still a lot of fat people and a lot of associated health issues. The cost of obesity in this country is estimated as being between four and nine billion dollars per year. It's a huge range, four to nine billion, but it's where you classify the different illnesses, and it depends on which survey you look at. Even if you go at the lower limit, $4 billion is a hell of a lot of money to spend on something that doesn't need to happen. Cardiovascular disease alone costs more than three billion. The human misery too that comes with being obese for many kids and adults is another intangible cost. But now we have a drug for that. GLP-1 is the magic ingredient. It regulates blood sugar levels and slows down the rate at which food leaves the stomach, thus making people fuller for longer. And apparently, according to those who've used it, it turns off the chatter in your head, the constant thinking about food. Well, if I have this and then I walk for an hour and then I'll be able to have something else. Ooh. Ooh, I'm not hungry now, but ooh, imagine what I could have for dinner. Planning the next meal before you've actually finished the one in front of you. It's that constant food chatter. I think Oprah was the first one to talk about it, how she never realised until she took the magic drug, that you didn't have to listen to that noise in your head, that other people didn't have it. So the GLP-1-mimicking drugs seem to be a powerful tool. They're actually effective. And after decades of research and money being poured into weight loss drugs, this one seems to work. More importantly, this one doesn't have the side effects of the speed drugs that were given out in the 70s as diet pills. It was basically methamphetamine. Some people are losing around 15% of their body weight or more after just over a year on the semaglutide. Wegovy became available to New Zealanders in July. It's not publicly funded. It's a weekly drug and comes at an ongoing cost of about $500 a month. Should it be funded? David Seymour, the Associate Minister for Health, seems to think so. In the past he said, well, if you spend a buck to save five, why wouldn't you? Although as he points out, Pharmac's decisions are independent of any ministers. The NHS in Britain has done the sums. If the weight loss drugs were prescribed to everyone who needed them according to the stringent criteria, the prohibitively expensive cost would bankrupt the NHS even after taking into account the cost of the health problems that they would inevitably solve. So you would have to do the sums for this country to work out whether it would pay off in the long run. If that's what it does, if, you know, one buck is going to save us five long term. If a huge cohort, in every sense of the word, of New Zealanders is going to live a better life, a healthier life as a result of the investment, surely it's worth it? But to get buy-in, you would have to get the support of the majority of New Zealanders. One in three adult New Zealanders is classified as obese, two in three aren't. And they might say, well, I'm doing everything right for my body. I'm doing the exercise and I'm not greedy. Some might well see obesity as a moral failing. Throughout history, it's been seen as a moral failing. One of the seven deadly sins is gluttony. In Dante's Inferno, the gluttons are consigned to the third circle of hell. Gluttons are people with uncontrolled appetites who worship food as a kind of God, according to Dante. Therefore, the gluttons' punishment in the third circle of hell, instead of eating fine delicate foods and wines, they're forced to eat filth and mud and be rained upon by foul smelling rain. Cerberus, the dog, ravages them and mauls them. It's a miserable punishment. Gluttons have always been seen as moral failures. Which may, I think, have been fair at a time where resources were scarce, and if you were wealthy, you got other people to get food for you and you ate it at the expense of the poor. But these days, when the food industry is making money out of processed food designed to hook you in and give you an insatiable appetite for more, I think we can take the moral failing out, can't we? Most people know what to do. There's far more to it than just calories in, calories out and more exercise, and even the makers of Wegovy and Ozempic and the like understand that too. They say it's not going to work on its own. It's the same with bariatric surgery, you have to do so much more than just stop the food going in. There is much, much more to it than that. If we do the sums, the NHS says they've done them and the cost is too high. But if we do the sums for this country, and ultimately, we spend a dollar to save five, why wouldn't we? Why wouldn't we put everybody who wants the Wegovy onto it? See omnystudio.com/listener for privacy information.

Trump unveils deal to expand coverage and lower costs on obesity drugs Wegovy and Zepbound. AP's Lisa Dwyer reports.

In this episode of The Body Pod, we sit down with Dr. Spencer Nadolsky — The GLP-1 Doc to uncover the truth about GLP-1 medications like Ozempic, Wegovy, and Mounjaro, and what they really mean for women's health, hormones, and sustainable weight loss.We dig into the real science behind appetite, metabolism, and obesity, and why weight gain isn't a failure of willpower but a matter of biology and hormones — especially for women in perimenopause and menopause. Dr. Nadolsky explains the myths around diet culture, Big Pharma, and compounded GLP-1 medications, plus how the medical system often overlooks women struggling with weight, fatigue, and hormonal changes. Whether you're curious about GLP-1 drugs, navigating menopause weight gain, or frustrated by conflicting weight loss advice, this conversation will leave you informed, empowered, and hopeful about your health journey.

Publicly funding weightloss drugs may not be the answer to the country's obesity problem. New Zealand has the third highest adult obesity rate in the OECD, with one in three adults classified as obese, and one in ten children. Associate Minister of Health David Seymour believes publicly funding things like Wegovy would help save money in the long run. But community leader and Founder of Butterbean Motivation, Dave Letele told Kerre Woodham that we can't prescribe our way out of this issue. While he's not against weightloss drugs, he says they don't change habits, mindsets, and they don't break cycles for children. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Van helmen uit Rheden, textiel uit Nijverdal en medische spalken uit Nijmegen. Defensie zoekt de samenwerking met regio’s als Brabant, Zeeland en Overijssel. Zo hoopt het leger veelbelovende bedrijven in het oog te krijgen die helpen de defensie-industrie op te schalen. Uiteindelijk is landelijke dekking nodig. FD-redacteur defensie Ria Cats vertelt wat de plannen zijn. Lees: Defensie en de regio, bouwen aan ecosystemen Wat eten we vanavond? Met die vraag verdienen vele tientallen receptensites en foodinfluencers een boterham. Nu willen supermarktketens daar een graantje van meepikken en dus slaan ze de handen ineen. Albert Heijn en Jumbo hebben — bij wijze van proef — al sinds 2021 koopknoppen staan op tien receptensites, zoals Leuke Recepten, Uit Paulines keuken of Laura’s Bakery. FD-redacteur Richard Smit vertelt hoe dat precies werkt. Lees: Dikkere boterham voor receptensites door de koopknop Het Zorginstituut worstelt met de vergoeding van eetlustremmers, die miljarden per jaar kunnen kosten. In de aanloop naar een advies over afslankinjecties Mounjaro en Wegovy spreekt de zorgpakketbeheerder alvast een waarschuwing uit. Voorlopig komen alleen obesitaspatiënten met ernstig overgewicht of gerelateerde ziektes in aanmerking voor vergoeding uit het basispakket. De potentiële gezondheidswinst is groot, maar de bijbehorende uitgaven ook, vertelt FD-redacteur Maarten van den Poll. Lees: Zorginstuut perkt vergoeding eetlustremmers in Redactie en montage: Sophia Wouda & Floyd Bonder Presentatie: Floyd Bonder See omnystudio.com/listener for privacy information.

New York's mayor-elect, Zohran Mamdani, is promising to tackle the city's soaring cost of living. Ed Butler looks at what his victory could mean for businesses.Also, Eli Lilly and Novo Nordisk agree to slash the cost of blockbuster weight-loss drugs like Ozempic and Wegovy under a new Medicare deal. And why Shein is facing a backlash in France.

GLP-1 medications like Ozempic®, Wegovy®, and Mounjaro® are changing the weight-loss landscape, but there's more to the journey than watching the scale move. In this episode, we break down 4 essential considerations everyone on a GLP-1 should know.With Mindy's science-based and trustworthy expertise, these are the considerations to protect your health during and after medication use:1. Preventing Lean Muscle Mass loss and Osteoporosis2. Managing GI Issues3. Preventing nutrient deficiencies 4. Build Healthy HabitsThis episode is supportive, judgment-free, and packed with actionable takeaways. Whether you're on a GLP-1, considering one, or supporting someone who is, this conversation will leave you feeling empowered and informed. References:Wong, ND, et al. US Population Eligibility and Estimated Impact of Semaglutide.  Cardiovasc Drug Ther. 2023Wong, ND, et al.  Population Eligibility and Estimated Impact of Semaglutide.  Cardiovasc Drug Ther. 2024 Chakhtoura, M., et al. Pharmacotherapy of obesity: EClinicalMedicine, 2023 Volek J, et al. Nutritional Considerations During Major Weight Loss.  Curr Nutr Rep. 2024Meslon E, et al.  What is the pipeline for future medications in obesity? Nature. 2024Martin CK, et al.  Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.  Nat Med. 2025Dilly A, et al.  Characteristics and food consumption for current, previous, and potential consumers of GLP-1s.  Food Quality and Preference.  2025;129;105507We are so glad you are here. Want to stay in touch?Follow us on social media: Sweat and Laughter podcast - @sweat.and.laughter.podcast Mindy - @strongover40_dietitian Cheryl - @training.with.cheryl Mindy & Cheryl - @mcfitadventures Email us: mcfitadventures@gmail.com Thank you so much for listening to Sweat & Laughter. M & C

Novo Nordisk has cut its forecast for the fourth time this year, after disappointing sales of its blockbuster drugs Wegovy and Ozempic. It underscores the challenges facing its new chief executive Mike Doustdar. He spoke to Bloomberg's Guy Johnson about the experience so far. See omnystudio.com/listener for privacy information.

Just over 18,000 New Zealanders have been prescribed the weight-loss drug Wegovy in the past three months, according to provisional data from Health New Zealand. Weight loss specialist, Doctor Gerard McQuinlan spoke to Ingrid Hipkiss.

In this episode of Finding Genius, host Richard Jacobs welcomes Dr. Sofia Din, anti-aging and longevity expert, for a deep and insightful conversation about GLP-1 agonists — the groundbreaking class of medications transforming the way we think about health, beauty, and aging. Dr. Din breaks down what GLP-1 agonists (like Ozempic, Wegovy, and Mounjaro) really do inside the body — beyond weight loss — exploring their potential role in metabolic health, skin rejuvenation, and longevity.

Are you doing "everything right"—eating clean, working out, and still battling fatigue, weight loss resistance, and relentless cravings? You're not alone. As women in perimenopause and menopause, shifting hormone balance can slow metabolism, alter hunger cues, and make it nearly impossible to lose weight the way we used to. In this episode, I sit down with Sarah Kennedy, CEO of Calocurb, to talk about a groundbreaking natural alternative to popular GLP-1 weight-loss drugs like Ozempic and Wegovy. We unpack how your body's own gut-brain connection can be reactivated using a 100% natural compound derived from hops, how GLP-1 hormones regulate hunger and satiety, and why this may be one of the most exciting breakthroughs for sustainable weight management—especially for women struggling with perimenopausal weight gain, fatigue, and digestive issues. What You'll Learn • The truth about GLP-1 hormones — what they do in your body, and how they naturally control appetite and fullness. • Why synthetic injectables like Ozempic can cause side effects — and how they differ from your body's own GLP-1 response. • The surprising power of bitter compounds — how natural plant extracts like Amarasate activate GLP-1, reduce cravings, and support a healthy gut-brain axis. • Why this approach is ideal for perimenopausal and menopausal women — discover how hormonal shifts, stress, and low energy change hunger and metabolism, and how to rebalance them naturally. • A simple timing strategy — when to take Calocurb to reduce nighttime cravings, support fasting, and eat less without feeling deprived. If you've been frustrated by weight loss resistance, low energy, or the feeling that your metabolism has "stopped working," this episode will show you why it's not your fault—and how to work with your body instead of against it. We'll walk through the science, the clinical research, and real-world strategies to help you reclaim your energy, rebalance your hormones, and restore your confidence without relying on synthetic solutions. Where you can find out more about Calocurb: www.calocurb.com use code MEG10 to save 10% https://www.facebook.com/calocurbGLOBAL/https://www.instagram.com/calocurb www.calocurb.com Stop wasting time (and money) on products that don't work. My Trusted Brands Guide is the exact list I share with my private clients — the skincare, supplements, food, and wellness tools that have been tested and proven to deliver results. No fluff. No guesswork. Just the brands you can finally feel good about using. ✨ Plus, I scored exclusive discounts from some of these companies just for my community.

Exclusive OTP Savings HTTPS://www.otplinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome back to the Dr. Kinney Show!In this solo episode, I'm diving deep into one of the most talked-about topics in wellness right now, GLP-1 medications, including Ozempic, Wegovy, and semaglutide. There's a lot of information (and misinformation) circulating about these drugs, and I want to explain how they actually work, when they can be incredibly effective, and when they can cause more harm than good.I break down the glucose-insulin connection, what insulin resistance really means, and why inflammation often begins with blood sugar imbalance. I also share how these medications can be used as a powerful tool for improving insulin sensitivity, reducing inflammation, and supporting hormone balance, when used thoughtfully and at the right time.In this episode, I discuss:How glucose and insulin function together to fuel your bodyWhat happens when insulin resistance develops and why it leads to fatigue, weight gain, and inflammationHow GLP-1 medications like semaglutide work to increase insulin sensitivityWhy microdosing or using the lowest therapeutic dose can be safer and more effectiveThe difference between short-term weight loss and long-term metabolic healthCommon side effects and how to avoid them with proper dosing and timingThe importance of building muscle and eating enough protein before starting a GLP-1 medicationHow these medications can reduce “food noise” and improve mental clarityThe unexpected benefits for hormone balance, PCOS, and menopause symptomsWhy GLP-1s should be seen as a supportive tool, not a quick fixWhether you're curious about GLP-1 medications for weight management, inflammation, or metabolic health, this episode will help you understand how to use them in a way that truly supports your body's healing process.https://www.thekinneyclinic.com/book

GLP-1 Agonists (Glucagon Like Peptide 1 Agonists) such as Mounjaro and Wegovy are becoming more widely used, here we cover examples of GLP1 Agonists, mechanism of action, as well as GLP1 agonist side effects. PDFs Available at: www.rhesusmedicine.com Consider subscribing on YouTube (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Patreon: https://www.patreon.com/rhesusmedicineBuy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 What are GLP-1 Agonists? 0:23 GLP-1 Agonist Mechanism of Action1:35 GLP-1 Agonist Indications & Uses2:37 GLP-1 Agonist Examples 4:05 GLP-1 Agonist Side EffectsPlease remember this podcast and all content from Rhesus Medicine is meant for educational purposes only and should not be used as a guide to diagnose or to treat. Please consult a healthcare professional for medical advice. ReferencesManne-Goehler, J., Franco, J., 2025. Side effects of GLP-1 receptor agonists. BMJ, 390:r1606. [online] Available at: https://www.bmj.com/content/390/bmj.r1606.full. (bmj.com)Collins, L., 2024. Glucagon-like peptide-1 (GLP-1) receptor agonists. StatPearls. [online] Available at: https://www.ncbi.nlm.nih.gov/books/NBK551568/. (NCBI)Andreasen, C.R., Andersen, A., Knop, F.K. & Vilsbøll, T., 2021. How glucagon-like peptide 1 receptor agonists work. Endocrine Connections, 10(7). [online] Available at: https://ec.bioscientifica.com/view/journals/ec/10/7/EC-21-0130.xml. (ec.bioscientifica.com)Diabetes UK, 2025. GLP-1 agonists – tablets and medication. [online] Available at: https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/glp-1. (Diabetes UK)

Danny Reweghs en Sebastien Mariën blikken vooruit op de komende week. Bpost en Novo Nordisk komen met resultaten. In Trends podcasts vind je alle podcasts van Trends en Trends Z, netjes geordend volgens publicatie.  De redactie van Trends brengt u verschillende podcasts over wat onze wereld en maatschappij beheerst.  Vanuit diverse invalshoeken en met een uitgesproken focus op economie en ondernemingen, op business, personal finance en beleggen.  Onafhankelijk, relevant, telkens constructief en toekomstgericht.  Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of The Fit Over 40 Reset Podcast, Brian from Applied Fitness breaks down one of the most misunderstood topics in women's health — how your metabolism really works and how GLP-1 support can help repair it.If you've heard the buzz about medications like semaglutide, Ozempic, or Wegovy and wondered whether they're the secret to lasting fat loss, this episode is for you. Brian explains how GLP-1 actually functions inside your body, why most women use it the wrong way, and how microdosing combined with strength training, hormone-friendly nutrition, and accountability coaching can reignite your metabolism — safely and sustainably.You'll learn:• What GLP-1 hormones do in your body and why they matter after 40• The difference between medical dependency and true metabolic repair• How to pair medication with movement and nutrition to prevent rebound weight gain• Why your metabolism isn't broken — it just needs the right resetIf you're tired of quick fixes and ready to understand the science behind real, lasting results, this episode will show you exactly how to make your metabolism work with you again.

Lately, it feels like everyone is talking about food noise. Thanks to GLP-1 medications like Ozempic and Wegovy, "food noise" has become the latest buzzword — and the newest thing people believe needs to be fixed with medication. But here's the truth: most people don't have a medical disorder that causes food noise. They have a body and mind that feel unsafe. Food noise isn't a disease — it's a signal. It's your body saying, "I don't trust you to feed me." In this week's episode, Deanna breaks down what's really behind constant thoughts about food, why medicating symptoms doesn't fix the cause, and what it actually takes to quiet food noise naturally — no prescription required. In this episode — "How to Stop Food Noise Without Medication" — you'll learn:

Medicare Advantage Minute:                                                                                                  Stop the Health Insurers' Raid on the Treasury! Your Medicare Benefits 2025:                                                                                                  Respiratory Syncytial Virus (RSV) Shot Stalker Suzy reviews Hey Moe's Melinda Caughill's appearance on the MLM Podcast! Prescription Drug Coverage Options are Shrinking for Medicare Shoppers Ozempic & Wegovy are now sold at Sam's Club for $500, joining Costco, GoodRx  and Novocare Pharmacy.    Contact me at: DBJ@MLMMailbag.com (Most severe critic: A+)                   Visit us on: BabyBoomer.ORG Inspired by: "MEDICARE FOR THE LAZY MAN 2025; SIMPLEST & EASIEST GUIDE EVER!" "MEDICARE DRUG PLANS: A SIMPLE D-I-Y GUIDE" "MEDICARE FOR THE LAZY MAN: BARE BONES!" For sale on Amazon.com. After enjoying the books, please consider returning to leave a short customer review to  help future readers. Official website: https://www.MedicareForTheLazyMan.com.

 Confused About Hormones or HRT? Dr. Nicole Lovat Helps You Navigate Midlife Health with Confidence and Clarity  Midlife health is not one-size-fits-all — and “normal” doesn't always mean optimal. When you understand your hormones, you can advocate for care that helps you feel your best — inside and out. 

Since January, one clinic in the UK has started prescribing the weight-loss medication Wegovy to 12-17 year-olds. For some, the results have been life-changing. But without evidence about the long-term impacts, is it safe?This podcast was brought to you thanks to the support of readers of The Times and The Sunday Times. Subscribe today: http://thetimes.com/thestoryGuest: Roisin Kelly, commissioning editor, The Sunday Times.Host: Manveen Rana.Producer: Taryn Siegel.Read more: The children taking Wegovy to turn their lives aroundFurther listening: Why weight loss drugs will change even more than you thinkPhoto: Times Media.Get in touch: thestory@thetimes.com Hosted on Acast. See acast.com/privacy for more information.

This Day in Legal History: October ManifestoOn October 30, 1905, Tsar Nicholas II of Russia issued the October Manifesto in response to mounting unrest and revolutionary fervor sweeping the Russian Empire. The 1905 Revolution had erupted earlier that year following the Bloody Sunday massacre, in which unarmed protesters were gunned down by imperial guards. Strikes, peasant revolts, and mutinies within the military and navy intensified public pressure for reform. The October Manifesto promised several liberalizing measures: the creation of a legislative Duma (parliament), expansion of civil liberties including freedom of speech, assembly, and conscience, and a commitment that no law would be enacted without the Duma's consent.Though revolutionary factions remained skeptical, the manifesto temporarily quelled widespread unrest and led to the formation of Russia's first constitutional structure. It marked the first time autocratic power in Russia was publicly limited by law, at least in theory. However, the tsarist regime maintained significant control: Nicholas retained the right to dissolve the Duma at will and manipulate election laws. Conservative forces viewed the manifesto as a concession made under duress, while radicals criticized it as too limited and unenforceable.The October Manifesto also split opposition forces. Some liberals, known as Octobrists, supported working within the new constitutional framework. Others, including the Bolsheviks and Socialist Revolutionaries, dismissed the document as a façade and continued to push for broader revolution. In legal terms, the manifesto introduced the concept of legislative consent into Russian governance, establishing a precedent for popular representation in lawmaking. Although the Duma's actual power remained constrained, the October Manifesto set the stage for future political conflicts that would culminate in the Russian Revolutions of 1917.The Trump administration's recent approvals for oil and gas leasing in Alaska and road development projects are drawing scrutiny from environmental groups, who say the decisions were made opaquely during a government shutdown, limiting their ability to challenge them in court. These projects include reopening leasing in the Arctic National Wildlife Refuge (ANWR), issuing permits for the 211-mile Ambler Road to mining sites, and approving a controversial land exchange to allow road construction through the Izembek National Wildlife Refuge wilderness. Environmental attorneys argue that key documents and analyses justifying these decisions remain unavailable, complicating legal strategies.The Interior Department, operating with a reduced staff, has only offered links to decision documents, providing little insight into environmental protections or regulatory compliance. Although these projects have been previously contested in court, the lack of transparency surrounding the latest approvals hinders further action. Some legal experts suggest potential conflicts of interest—such as the U.S. acquiring a stake in a company tied to the Ambler Road—could be grounds for future lawsuits. Additionally, the Izembek land swap may face legal challenges for bypassing required congressional approval.Environmental Groups Challenged in Fighting Trump's Alaska MovesThree former Morgan Stanley financial advisers are suing the U.S. Department of Labor over a recent advisory opinion that they argue unlawfully shields the bank from arbitration claims related to unpaid deferred compensation. Filed in Manhattan federal court, the lawsuit alleges that the Labor Department's September 9 finding—that Morgan Stanley's deferred compensation plan does not qualify as an employee benefit pension plan under ERISA—conflicts with two prior court rulings that said it does.The plaintiffs, Steve Sheresky, Jeffrey Samsen, and Nicholas Sutro, say the opinion was “arbitrary and capricious” and would undermine their efforts, and those of other former employees, to arbitrate claims over canceled or unpaid compensation. They also claim Morgan Stanley is already using the Labor Department's stance to dismiss ongoing claims and seek reimbursement of legal costs.Though Morgan Stanley is not a defendant in the suit, the plaintiffs argue the agency overstepped its authority and are asking the court to revoke the advisory opinion under the Administrative Procedure Act. The case, Sheresky et al v. U.S. Department of Labor, raises broader questions about administrative agencies issuing legal interpretations that can influence private litigation outcomes without proper judicial or legislative review.Former Morgan Stanley advisers sue US Labor Department | ReutersEli Lilly has announced a new partnership with Walmart to offer its weight-loss drug Zepbound at discounted, direct-to-consumer prices through Walmart pharmacies nationwide. This marks the first time customers using the LillyDirect platform can pick up the medication in person at a retail location. The lowest dose of Zepbound will be available for $349 per month for self-paying patients.The move is part of Lilly's broader strategy to expand access and boost market share in the competitive obesity drug space, currently valued at around $150 billion. Zepbound competes directly with Novo Nordisk's Wegovy, but recent data suggests Lilly has pulled ahead in prescriptions, despite Novo's earlier market entry.Lilly reported that around 35% of Zepbound prescriptions in Q2 came from cash-paying customers using LillyDirect. Both Lilly and Novo have also made their weight-loss drugs available through various telehealth platforms, further expanding patient access.Lilly, Walmart launch first retail pick-up option for weight-loss drug | ReutersA piece I wrote for Forbes earlier this week looks at the escalating tensions surrounding digital services taxes (DSTs), with France once again moving to raise its DST—from 3% to 15%—primarily targeting U.S. tech giants like Google, Meta, and Amazon. The U.S. has responded with familiar threats of tariffs and trade retaliation, repeating a now well-worn pattern of diplomatic pushback without addressing the underlying issue. That issue is structural: the global tax framework was built around physical presence, but today's digital economy allows companies to generate profits in countries where they have no offices, employees, or infrastructure.As frustration builds in countries watching tech firms reap profits without corresponding local tax contributions, DSTs have become a tool to reclaim taxing rights. In response, nearly 140 countries have worked through the OECD to build a two-pillar international solution. Pillar One aims to reallocate taxing rights based on where users are located; Pillar Two introduces a global minimum tax. Yet, while other countries move forward, the U.S. continues to resist fully embracing Pillar One—out of concern for political optics and revenue loss.That resistance is counterproductive. By refusing to commit to a multilateral framework, the U.S. is guaranteeing the very outcome it opposes: a fragmented global tax landscape where each country sets its own rules. The current whac-a-mole strategy—reacting to every unilateral move with threats—offers no long-term protection for U.S. companies and only heightens global instability. It's time for the U.S. to stop playing defense and help finalize a framework that reflects the realities of the digital economy.Whac-A-Mole Taxation Battles Will Persist Without A Global Deal This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

From the skyrocketing costs of drugs like Ozempic and Wegovy to the moral and economic debate over obesity as a disease, Michael explores both sides of this billion-dollar question: "Should Congress mandate Medicaid to cover weight-loss medications like GLP-1s?" Listen to his take, then vote on today's poll at smerconish.com. He also revisits yesterday's poll question on the political buzz around Kamala Harris, Gavin Newsom, and the 2028 race — plus some media mayhem from New York's mayoral contest. Please rate, review, and share this podcast. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

“It's kind of a miracle, frankly,” says Dr. John Buse, a distinguished professor at the University of North Carolina School of Medicine, referring to the effectiveness of GLP-1 receptor agonist medications such as Ozempic in treating type 2 diabetes, promoting significant weight loss, and reducing cardiovascular risk. As a physician scientist for the last three decades at UNC, Dr. Buse has played a key role in ushering in this new era of diabetes care, leading or participating in over 200 clinical studies on this class of drugs and others. “Nothing has impacted diabetes care like the GLP-1 receptor agonists. I have lots of patients whose diabetes was never well controlled who have seen all their metabolic problems essentially resolved.”  In this fascinating conversation with Raise the Line host Lindsey Smith, Dr. Buse not only explains how these drugs work, but also provides a clear-eyed look at side effects, and addresses issues of cost and access. Join us for the remarkable story – including the role played by Gila monsters -- behind one of the biggest developments in medicine over the past several years from a world renowned diabetes researcher and clinician. Mentioned in this episode:UNC School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Zayıflama iğneleri gerçekten çözüm mü, yoksa yeni bir diyet kültürü formu mu?Bu bölümde, son yılların en popüler konularından biri olan GLP-1 iğnelerini konuşuyoruz. Ozempic, Wegovy, Mounjaro gibi isimlerle karşımıza çıkan bu ilaçlar aslında nereden çıktı, ilk başta hangi hastalıklar için geliştirildi ve nasıl oldu da “zayıflama iğnesi”ne dönüştü?Bilimsel ama sade bir dille, tokluk hissinin beyinde nasıl oluştuğunu, GLP-1 hormonunun vücuttaki rolünü, ve bu ilaçların davranışsal etkilerini ele alıyoruz.Ayrıca bir yeme bozukluğu koçu olarak bu tür müdahalelerin, özellikle geçmişinde diyet kültürüyle mücadele etmiş kişilerde hangi duygusal tetiklemeleri yaratabileceğinden de bahsediyorum.

In part 2 of this GLP-1 series, Ted shares two real-life case studies that reveal when weight loss drugs like Ozempic, Wegovy, and Mounjaro deliver results—and when they don't. Discover the surprising lessons that make the difference. If you missed part 1, go back to hear Ted break down the dos and don'ts of these drugs, how they work, the results people are seeing, and the lifestyle shifts that ensure lasting success. Listen now!  Click here for part 1:   

Millions of adults take popular drugs like Ozempic, Wegovy, and Mounjaro to treat chronic conditions and/or lose weight. The GLP-1 medications have made headlines for their effectiveness, and new studies have shown that some of them can also curb alcohol and drug consumption and lower the risk of a heart attack. But not everyone has equal access to the medications. While some patients are able to obtain them through their health care providers, others have turned to online platforms that don't require prescriptions. In many cases, they can also be cost prohibitive: Ozempic, for example, can cost up to $1,000 per month without insurance. This hour, we explore the latest with these medications: what they treat, how they work, and who should be able to access them. Our guests: Zachary Burns, D.O., assistant professor of family medicine at the University of Rochester Medical Center and associate director of Moving Medicine Forward  Erica Davis, patient who uses weight loss medication, theater professional, educator, and mother Molly Ranney, MS, RD, CDN, CSOWM, lead dietitian for the Bariatric Center at Highland Hospital Kaci Schiavone, M.D., assistant professor in the Department of Surgery, Bariatric/GI at the University of Rochester Medical Center ---Connections is supported by listeners like you. Head to our donation page to become a WXXI member today, support the show, and help us close the gap created by the rescission of federal funding.---Connections airs every weekday from noon-2 p.m. Join the conversation with questions or comments by phone at 1-844-295-TALK (8255) or 585-263-9994, email, Facebook or Twitter. Connections is also livestreamed on the WXXI News YouTube channel each day. You can watch live or access previous episodes here.---Do you have a story that needs to be shared? Pitch your story to Connections.

Way back when we started this podcast, in Season 1, this film was brought up, and now it's finally happening. Before we launch in Zarch, let's wrap off Zombuary with our masterpiece episode, "28 Days Later". This film avoids the common themes of the start of the zombie apocalypse, and makes you ask yourself, what would it be like if you woke up from a coma, and it already is happening? How much of Cillian Murphy's dong do you get to see? What did Brandon's mom initially think of this film? And have you talked to a pharmacist to see if Wegovy is right for you? Tune in this week to find out all this and more, but only on "The Good, The Bad, and The Movies"! P.S. Check out these links to stay connected with TGTBTMDiscord: https://discord.gg/rKuMYcKvYoutube: https://youtu.be/ltj-J72Em48

What if everything you thought GLP-1s were for—was just the beginning? I sit down with Dr. Rocio Salas-Whalen, a board-certified endocrinologist and obesity medicine specialist with over 15 years of experience prescribing GLP-1s, to explore what these medications are really doing in the body. Whether you're already taking Ozempic or Wegovy, considering starting, or just curious, this conversation will change how you think about metabolism, hormones, and health. Dr. Salas-Whalen explains how GLP-1s go far beyond appetite suppression and weight loss—they can impact fertility, inflammation, autoimmune conditions, and even how your brain responds to addictive cravings and stress. You'll also hear how body composition, not BMI, is the future of metabolic health, and what to ask your doctor before starting GLP-1s.

Send us a textDr. Acosta returns to Causes or Cures to talk about the next big leap in obesity research: using genetics and machine learning to predict which patients will get side effects to popular GLP-1 weight-loss medications like Wegovy and Zepbound. Previously, he was on Causes or Cures to discuss your individual obesity type. He and his team are uncovering why some people experience major weight loss while others face tough side effects—especially nausea. The goal? True precision medicine for obesity: matching the right treatment to the right person before treatment even begins. (You can learn more about their available tests and company here.) Topics We DiscussDr. Acosta's background and what drew him to obesity researchWhy not all obesity is the same—and why that matters for patients and doctorsThe most common questions patients ask about GLP-1 drugs like Wegovy and ZepboundHow big a problem side effects like nausea really are in practiceNew research using genetic markers to predict who's more likely to experience side effectsWhether eating style affects nausea and how Dr. Acosta coaches patients on nutrition while using these medicationsThe possibility of genetic testing before prescribing GLP-1sWhat we know about rarer side effects, from vision to hearing changes, if he thinks more side effects will emergeWhat “satiation” (feeling full) means and why it varies so much between peopleHow genetic risk and satiation scores could determine which obesity treatment works bestDr. Acosta's thoughts on obesity prevention, especially on renewed energy to take on the unhealthy food industryThe persistence of stigma—why “willpower” doesn't tell the whole storyWhether the current obsession with obesity drugs distracts from prevention, nutrition, and community health Listen if you've ever wondered:Why GLP-1 drugs don't work the same for everyoneWhat your genes have to do with weight loss, feeling full and side effectsHow soon doctors could use genetic tests to personalize obesity treatmentWhether prevention is being overshadowed by the pharma spotlightWhy it mattersObesity isn't a one-size-fits-all condition—and neither should its treatment be. Dr. Acosta's research could mark a turning point in how we approach weight loss: scientifically, compassionately, and individually. Dr. Acosta is a Consultant of Gastroenterology and Hepatology at the Mayo Clinic, as well as an Associate Professor of Medicine. His research focus is on gastrointestinal physiology and the complexity of food intake regulation as it relates to obesity. You can learn more about his work here.You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her WEEKLY newsletter here! (Now featuring interviews with top experts on health you care about!)Support the show

Weight-loss drugs like Ozempic®, Wegovy®, and Mounjaro™  or GLP-1 can reset your appetite—but only you can rewire your brain. In this episode, I'm showing you how to use your quiet-appetite season on Ozempic as a bridge, not a crutch. You'll learn how to shift from the Dieter's Mindset to the Stop Dieting Forever Mindset and build habits that actually stick while your food noise is quiet. ✨ What You'll Learn in This Episode: Why Ozempic can change your biology—but not your beliefs How to reprogram habits while your appetite is quiet The difference between the Dieter's Mindset and the Stop Dieting Forever Mindset How to apply the Four ForeverWell Essentials  A guilt-free way to enjoy treats—with grown-woman boundaries How to use self-coaching to manage stress and cravings The TikTok story that shows what happens when you skip the mindset work ====================== FEATURED ON THE SHOW / RESOURCES

Maigrir rapidement. C'est la promesse de nombreux influenceurs faisant la promotion du Wegovy ou de l'Ozempic sur les réseaux sociaux. Ces médicaments, à destination des obèses et des diabétiques, sont utilisés par des personnes non malades pour perdre du poids de façon spectaculaire. A l'ère du “Skinny Tok”, cette tendance qui fait l'apologie de la maigreur sur TikTok, ces traitements “miracle” jouissent d'une grande publicité. Certains font tout pour se les procurer créant des pénuries pour les personnes diabétiquesEffets secondaires, médicaments frauduleux, mauvaise utilisation du traitement … Maigrir à tout prix n'est pas sans danger. Code source décortique le phénomène derrière ces médicaments minceurs avec Nicolas Berrod, journaliste spécialiste des sujets de santé au Parisien. Crédits. Direction de la rédaction : Pierre Chausse - Rédacteur en chef : Jules Lavie - Reporter : Barbara Gouy - Production : Thibault Lambert, Pénélope Gualchierotti et Anaïs Godard - Réalisation et mixage : Julien Montcouquiol - Musiques : François Clos, Audio Network - Archives : TikTok. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Are Ozempic, Wegovy, and Mounjaro really the miracle solution for weight loss? In part 1 of this 2 part series, Ted breaks down how GLP-1 drugs work, the results people are seeing and the potential downsides no one talks about. Plus, the lifestyle shifts that ensure lasting success. Listen now! 

This is a free preview of a paid episode. To hear more, visit abbieattwoodwellness.substack.comRagen Chastain is back to continue our conversation about weight, health, and diet culture — this time answering listener questions about the GLP-1s you've been hearing so much about: Wegovy, Ozempic, and other weight-loss drugs.Following up on last week's episode, Ragen helps us separate hype from reality. We dive into how these drugs actually work — and don't — their risks and side effects, and the broader context around the pharmaceutical industry and public discourse on weight.In this episode, we cover:What GLP-1s actually are and how they function in the bodyThe side effects and potential health risks of these drugsHow effective they really are for long-term weight managementWhat happens when weight loss plateaus while taking themThe impact of pharma companies, marketing, and the weight-loss industryThe shortages affecting diabetics who rely on GLP-1s for medical reasonsTune in to get a clear, evidence-based perspective on the weight-loss drug craze, and to continue unpacking the bigger conversation about weight, health, and stigma.Support the show: Enjoying this podcast? Please support the show on Substack for bonus episodes, community engagement, and access to "Ask Abbie" at abbieattwoodwellness.substack.com/subscribe Apply for Abbie's Group Membership:Already been at this anti-diet culture thing for a while, but want community and continued learning? Apply for Abbie's monthly membership: https://www.abbieattwoodwellness.com/circle-monthly-group Social media:Find the show on Instagram: @fullplate.podcastFind Abbie on Instagram: @abbieattwoodwellness Podcast Cover Photography by Anya McInroyPodcast Editing by Brian WaltersThis podcast is ad-free and support comes from your support on Substack. Subscribe HERE.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Ever notice how travel can completely throw off your routine—especially when you're on a weight loss plan? Between airports, restaurants, and unpredictable schedules, it can feel like all your progress is at risk the moment you pack your bags.In this episode, we're tackling one of the biggest challenges my patients—and honestly, I—face when it comes to staying consistent: travel. Whether your trip is for work, vacation, or a bit of both, this one's for you.We'll cover:Smart eating while travelingPlanning for balanced meals on the goStaying active during your tripTraveling smoothly with your medicationsWhy you shouldn't change your dose before travelingKeeping your healthy habits going while awayI've learned a lot from my own travels—speaking at conferences, attending events, and doing advocacy work—and I've seen what works for both me and my patients who want to enjoy their trips without losing progress.We'll get into simple, practical strategies to stay consistent with nutrition, movement, medication, and mindset—the four pillars I use in obesity medicine. And as a bonus, I'll share key tips for anyone using Wegovy or Zepbound: how to pack them, store them, and stay on track with dosing while you're away.So if you've got a trip coming up and want to come home feeling good, energized, balanced, and still on track, this episode will walk you through exactly how to make that happen.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

n the News.. COVID-19 & T1D, Ozempic Pill Progress, Faster Insulin, “Beyond Misconceptions,” and More It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new study looks at the link between COVID-19 and very young children, Lilly moves ahead with their Ozempic oral pill, ultra-rapid insulin clears another hurdle, Beyond Type 1 launches a new campaign and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX https://www.scientificamerican.com/article/advances-in-type-1-diabetes-science-and-tech/ This article is part of “Innovations In: Type 1 Diabetes,” an editorially independent special report that was produced with financial support from Vertex. XX More evidence linking COVID 19 to type 1 diabetes.. but still exactly why is a mystery. During the COVID-19 pandemic, there was an unexpected increase in the number of cases of type 1 diabetes in Sweden, particularly among children under 5 and young adult men. The infection accelerated the onset of diabetes among children between the ages of 5 and 9. The researchers looked at data from a 17-year period on the incidence of type 1 diabetes among all people under the age of 30 in Sweden. In addition, they compared the risk of developing diabetes among 720,000 individuals with positive COVID-19 tests against a control group of 3.5 million people. The findings are published in the journal Diabetologia. The number of diabetes cases increased by 12% in 2021 and 9% in 2022 compared with previous years. In 2023, the number of cases was back to a normal level. Despite this, the researchers cannot distinguish a clear connection between COVID-19 infection and diabetes, except for children between 5 and 9 years old. They had an increased risk of type 1 diabetes about one month after a COVID-19 infection even though their total risk did not increase. "However, it's clear that the COVID-19 vaccine can be ruled out as a cause of the increase in diabetes cases. The recommendation for the age group where we saw the strongest increase was not to get vaccinated. In addition, other studies on adults have shown that vaccination reduces the risk of developing type 1 diabetes after a COVID infection." https://medicalxpress.com/news/2025-10-diabetes-young-people-pandemic.html XX A new gene therapy approach aimed at protecting people with type 1 diabetes from developing diabetic kidney disease—a serious and common complication of the condition, has shown promising results in a University of Bristol study. Findings from this new study, published in Molecular Therapy, demonstrated a 64% reduction in a damage indicator for kidney disease, paving the way for a potential new treatment. The study, explored the potential of delivering a protein called VEGF-C directly into kidney cells. Previous studies have shown VEGFC could protect against kidney disease as it helps keep blood vessels in the kidney filter healthy, repairing early signs of diabetes-related kidney damage. https://medicalxpress.com/news/2025-10-gene-therapy-kidney-disease-diabetes.html XX The FDA has agreed to consider Afrezza inhaled insulin for children and teens. The company said in August that it submitted a supplemental Biologics License Application (sBLA) for Afrezza in the pediatric population and it's been assigned a decision deadline date of the end of May, 2026. Afrezza first recieved FDA approval for adults (age 18 and up) in June 2014 https://www.drugdeliverybusiness.com/fda-accepts-application-mannkind-inhaled-insulin-kids/ Update on inhaled insulin for kids.. in the open-label, randomized, phase 3 INHALE-1 clinical trial Afrezza demonstrated safe and effective replacement for rapid-acting meal insulin in children with type 1 diabetes (T1D and demonstrates comparable glycemic control to injected rapid-acting insulin. The INHALE-1 clinical trial assessed the safety and efficacy of Afrezza among children and adolescents with T1D, including a total of 230 patients aged 4 to 17 years. Researchers used basal injected insulin and randomly assigned inhaled insulin or rapid-acting analogue for meals, evaluating the change in hemoglobin A1c levels at 26 weeks. After completing 26 weeks of randomly assigned treatment with either Afrezza or rapid-acting insulin injections combined with basal insulin, participants continued receiving the inhaled insulin until week 52 for an extension phase to evaluate the safety and effectiveness of Afrezza with continued use.1,2 https://www.pharmacytimes.com/view/inhaled-insulin-demonstrates-comparable-safety-lung-function-and-efficacy-to-injectable-insulin-in-type-1-diabetes XX Eli Lilly released the results of two new Phase 3 trials of an experimental GLP-1 pill that the company says could become a “foundational treatment” for type 2 diabetes. The Indianapolis-based drugmaker plans to submit global regulatory applications for orforglipron in the treatment of type 2 diabetes next year. The company said it will seek approval of the drug as an obesity medication by the end of 2025. Lilly is trying to build on the success of its Mounjaro/Zepbound franchise by offering patients a pill instead of an injection. But the company is trailing behind rival Novo Nordisk in developing an oral alternative, and data released so far has raised some skepticism among investors. A study released in August showed that orforglipron could help patients lose an average of about 12% of their body weight. Wall Street had been expecting more; Lilly's injectable drug Zepbound produced weight loss of as much as 21%, and Novo Nordisk has achieved 15% weight loss percentages for both oral and injectable versions of its Wegovy medication.   https://www.fiercebiotech.com/biotech/eli-lillys-orforglipron-bests-farxiga-padding-oral-glp-1-case-pair-phase-3-diabetes-wins   XX XX UF Health Cancer Center researchers have found a surprising culprit behind common health problems such as obesity, diabetes and fatty liver disease: silent genetic glitches in the blood system that occur naturally as people age. The findings, published in the Journal of Clinical Investigation, mean that in the future, simple blood tests could be developed to identify people most at risk early on, helping prevent chronic illnesses and cancer through strategies like diet or lifestyle changes. As people age, stem cells in the bone marrow that produce blood cells gradually accumulate mutations in their DNA. Most mutations don't cause any issues, but sometimes blood stem cells with a mutation can start crowding out their peers. Called clonal hematopoiesis, this condition affects about 10% of older people and is associated with an increased risk of blood cancers like leukemia. It's also linked to a higher risk of obesity and diabetes. But the prevailing thinking was that obesity and related conditions promoted blood cell changes, not the other way around. The new study reverses that. The implications could be far-reaching, particularly as obesity has now overtaken smoking as the most significant and preventable risk factor for cancer. The team is studying how the mutations drive disease. Next, they plan to test how drugs like those commonly used to treat diabetes and new popular weight loss drugs might help reverse or prevent diseases caused by blood cell changes. https://medicalxpress.com/news/2025-10-hidden-blood-mutations-obesity-diabetes.html XX A new ultra rapid insulin continues to move forward. A phase 3 clinical trial of BioChaperone Lispro (liss-pro) conducted in China found it safe and effective compared with Humalog along with a significant reduction of the rise of blood glucose after a test meal.     These results complete and confirm the positive outcomes previously obtained with THDB0206 injection in people with Type 2 Diabetes It combines Adocia's proprietary BioChaperone® technology with insulin lispro, the active ingredient in the standard of care, Humalog® (Eli Lilly).   This innovative formulation acts significantly faster https://pharmatimes.com/news/ultra-rapid-insulin-shows-promise-in-phase-3-trial-for-type-1-diabetes/   Poor blood sugar control in adolescent patients with type 1 diabetes (T1D) may be associated with a higher risk of neuropathy in adulthood, according to recent research from the University of Michigan.1 The study included children diagnosed with T1D between 1990-1992 who were recruited into the Cognition and Longitudinal Assessment of Risk Factors over 30 Years cohort study in Australia. Investigators collected HbA1c from medical records, and microvascular complications were assessed through self-reports, clinical screenings, retinal photographs, and urinary albumin-creatinine testing.3   A total of 30 children were recruited from the original cohort with a mean diagnosis age of 2.9 years. After an average of 29.7 years (standard deviation [SD]: 3.9 years), 33% of participants (n = 13) developed neuropathy, 63% (n = 19) developed diabetes-related eye disease, and 10% (n = 3) developed neuropathy.3 Mean HbA1c estimates during adolescence (9% [74.9 mmol/mol]; 95% CI, 8.6-9.3 [70.5-78.1]) were substantially higher than childhood (8.2% [66.1 mmol/mol]; 95% CI, 7.8-8.5 [61.7-69.4]; P

This week we're diving into one of the biggest health conversations of the year as we explore GLP 1 weight loss drugs. From Ozempic to Wegovy these medications have changed how we think about food, weight and willpower but they've also raised big questions about what healthy really means. Dr Jack Mosley joins us to unpack the science behind these drugs, the truth about food noise, muscle loss and long term side effects, and what happens when you stop taking them. We also look at natural ways to support GLP 1 function through diet and lifestyle. As these drugs become more accessible and more widely marketed are they a genuine breakthrough or another quick fix in disguise Learn more about your ad choices. Visit podcastchoices.com/adchoices

Losing weight is hard. That's probably why almost three-fourths of American adults are overweight or obese. On this episode, we speak with a distinguished doctor and former FDA commissioner who has personal experience struggling with the scale. In this discussion of popular weight-loss drugs like Wegovy, we tackle the biology of weight. We also interview […]

Episode 1809 - brought to you by our incredible sponsors: True Classic- TrueClassic.com/HARDFACTOR to try them out for yourself. Hydrow- Go to Hydrow.com and use code HARDFACTOR to save up to $450 off your Hydrow Pro Rower! DaftKings- Download the DraftKings Casino app, sign up with code HARDFACTOR, and spin your favorite slots! The Crown is Yours - Gambling problem? Call one eight hundred GAMBLER Lucy- Let's level up your nicotine routine with Lucy.  Go to ⁠⁠Lucy.co/HARDFACTOR⁠⁠ and use promo code (HARDFACTOR) to get 20% off your first order. Must be of age-verified. Better Help - Our listeners get 10% off their first month of online therapy at BetterHelp dot com slash HARDFACTOR Timestamps: 00:00:00 Timestamps 00:04:10 Happy birthday to Wes' Mom 00:05:50 Costco to begin selling Ozempic and Wegovy for half off 00:18:15 Scientists release a report that humans have a lot of alien DNA thanks to abductions 00:24:15 Good old-fashioned cigarette smuggling drone operation in Lithuania  00:28:20 Recall on Canadian thc pouch products Chillows for having way more mgs than advertised 00:32:15 20k bounty placed on man accused of cutting off sea lion's head in front of daughter  Thank you for listening!! If you're still reading, join our community at patreon.com/hardfactor to get access to bonus podcasts, discord chat, and much more... but Most importantly: HAGFD!! Learn more about your ad choices. Visit megaphone.fm/adchoices